Annual spending on biopharmaceuticals in the United States (2011) is over $60 billion and rising much faster than traditional chemical pharmaceuticals. Generic versions of biopharmaceuticals known as biosimilars have been on the market in Europe since 2006, and despite saving money have not attained the same market success. Congress has now charged the FDA with responsibility for approving biosimilars in the United States. To understand what managed health care organizations (MCO) think about biosimilars and how they may respond to the availability in the United States, in-depth interviews were conducted with key MCO decision makers. The data showed that MCOs are highly interested in biosimilars and their potential for cost savings. A FDA designation of interchangeable will be the most important driver of market uptake. Without such a designation a MCO's ability to encourage utilization is based upon physician and patient perception of safety and efficacy, and patient financial incentives.
|School:||University of Alaska Anchorage|
|School Location:||United States -- Alaska|
|Source:||MAI 49/06M, Masters Abstracts International|
|Subjects:||Medicine, Health sciences, Public health|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
supplemental files is subject to the ProQuest Terms and Conditions of use.